TITLE

Consumer Advertising of Psychiatric Medications Biases the Public Against Nonpharmacological Treatment

AUTHOR(S)
Lacasse, Jeffrey R.
PUB. DATE
November 2005
SOURCE
Ethical Human Psychology & Psychiatry;Fall/Winter2005, Vol. 7 Issue 3, p175
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In the United States, antidepressant medications are heavily promoted through direct-to-consumer advertising, which is regulated by the Food and Drug Administration (FDA). Advertisements for selective serotonin reuptake inhibitors frequently contain information inconsistent with the scientific evidence on the treatment of depression with antidepressants. The information presented serves to promote the use of antidepressants by biasing the public against nonpharmacological treatment of depression. While the FDA enforces regulations requiring fair and balanced presentation when comparing one medication to another, there appears to be no action taken against pharmaceutical companies that distort scientific evidence in order to disparage nonmedical approaches to depression.
ACCESSION #
25237118

 

Related Articles

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Sep2005, Vol. 40 Issue 9, p14 

    Shares insights into the regulatory consequences of direct-to-consumer advertising in the U.S. Criticisms of legislators against pharmaceutical marketing practices; Responses to the job monitoring of the Food and Drug Administration; Scrutiny against drug advertising on television.

  • Consumer Rx ads right prescription for media. Wilke, Michael // Advertising Age;3/25/1996, Vol. 67 Issue 13, p12 

    The article reports that direct-to-consumer advertising of prescription drugs may experience a major boom if the U.S. Food and Drug Administration (FDA) loosens up the rules concerning advertisement of drugs. The FDA has been criticized by many groups for its prescription-drug ad rules that...

  • Abrams is 'pleased' with PhRMA'sDTC guidelines. Dickinson, James G. // Medical Marketing & Media;Nov2005, Vol. 40 Issue 11, p14 

    Comments on the reaction of the Food and Drug Administration to Pharmaceutical Research and Manufacturers of America's direct-to-consumer (DTC) pharmaceutical advertising guiding principles in the U.S. Statement of Division of Drug Marketing, Advertising and Communications director Tom Abrams on...

  • Vantage point. Selchau-Hansen, Susanna // Medical Marketing & Media;Sep2010, Vol. 45 Issue 9, p29 

    In this article, the author reflects on the alternative methods of pharmaceutical advertising in the U.S. The author observes that due to the regulations imposed by the U.S. Food and Drug Administration (FDA) on direct-to-customer (DTC) advertising, in-flight campaign optimization has remained...

  • FDA goes direct to consumers for views. Arnold, Matthew // Medical Marketing & Media;Oct2005, Vol. 40 Issue 10, p28 

    Reports that the Food and Drug Administration has asked the public if its current enforcement powers are adequate to police direct-to-consumer advertising in the U.S. Schedule of a public hearing of the agency on direct-to-consumer advertising; Presentation of risk information in advertising;...

  • FDA hearings could bring DTC regulations. Thomaselli, Rich // Advertising Age;10/3/2005, Vol. 76 Issue 40, p8 

    This article reports that the U.S. Food and Drug Administration (FDA) will hold a public hearing in November 2005 in Washington to discuss direct-to-consumer (DTC) advertising. In September 2003, the FDA heard input during a two-day public hearing and said it would produce guidelines for the...

  • DRUGMAKERS SPAR WITH THE FDA OVER PROPOSED DTC ANIMATION STUDY. McCaffrey, Kevin // Medical Marketing & Media;Dec2016, Vol. 51 Issue 12, p16 

    The article reports that drugmakers are making a motion over the U.S. Food and Drug Administration's planned studies examining the use of animation in direct-to-consumer (DTC) advertising.

  • Serotonin and depression: a disconnect between the advertisements and the scientific literature. Lacasse, Jeffrey R.; Leo, Jonathan // PLoS Medicine;Dec2005, Vol. 2 Issue 12, pe392 

    The article examines whether there is a congruence between claims made in serotonin reuptake inhibitor advertising with the scientific literature. It discusses the serotonin hypothesis advocated by Joseph Schildkrauit in 1965. A list of selected quotations related to serotonin and...

  • Active metabolite gives new life to antidepressant. Belden, Heidi // Drug Topics;4/14/2008, Vol. 152 Issue 5, p16 

    The article reports that the desvenlafaxine, a serotonin-nonrepinephrine reuptake inhibitor (SNRI) from Wyeth will go off the patent and will be marketed under the name Pristiq, an active metabolite included in the company's extended-release SNRI venlafaxine. The drug is said to be approved by...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics